Comparative Fasting Bioavailability of 2 Different Betahistine Dihydrochloride 24-mg Tablets: A Single-Dose, Randomized-Sequence, Open-Label, 2-Period Crossover Study in Healthy Thai Volunteers

Authors

  • Pinpilai Jutasompakorn Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700

Keywords:

Betahistine dihydrochloride, bioequivalence

Abstract

Objective: To evaluate the bioequivalence of 24 mg betahistine dihydrochloride tablets between the test product (Stei®) and the reference product (Serc®) in healthy Thai volunteers.
Methods: This was an open-label, randomized sequence, single-dose, two-period crossover study in 24 healthy volunteers. Half of the volunteers received a single dose of test product 24 mg and then reference product 24 mg after a minimum 7-day washout period. The remaining half of volunteers received the reference product first and then the test product with the same washout period. Blood samples were obtained at pre-dose and over 14 hours after dosing. Plasma concentrations of 2-pyridylacetic acid (2-PAA), a major metabolite of betahistine were quantified by using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Tolerability in volunteers was assessed during the study.
Results: Statistical comparison of the main pharmacokinetic parameters showed no significant difference between test and reference. The geometric mean ratios of 2-PAA between the test and reference products were 96.44%, 96.99%, and 94.56% for Cmax, AUC0-t, and  AUC0-∞, respectively. These pharmacokinetic parameter values lie within the FDA and European Medicines Agency specified bioequivalence limit (80-125%). No serious adverse events related to the studied drugs were found.
Conclusion: It can be concluded that these two betahistine dihydrochloride products were considered bioequivalent.

Downloads

Published

09-06-2016

How to Cite

Jutasompakorn, P. (2016). Comparative Fasting Bioavailability of 2 Different Betahistine Dihydrochloride 24-mg Tablets: A Single-Dose, Randomized-Sequence, Open-Label, 2-Period Crossover Study in Healthy Thai Volunteers. Siriraj Medical Journal, 68(3), 142–147. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/58338

Issue

Vol. 68 No. 3 (2016): May-June

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.